Living Cell gains approval for DiabeCell New Zealand trials
This article was originally published in Scrip
Executive Summary
Biotechnology company Living Cell Therapeutics has received clearance to conduct a Phase I/IIa trial of its insulin-producing cell product, DiabeCell, in New Zealand.